Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia

Article Oncology

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Anjali S. Advani et al.

Summary: The study evaluated the efficacy of Blinatumomab as induction and consolidation therapy in older patients with Philadelphia chromosome-negative B-acute lymphoblastic leukemia. Results showed Blinatumomab had good tolerability and effectiveness in treatment, with some patients achieving complete remission, and encouraging 3-year disease-free survival and overall survival rates.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.

Nicholas James Short et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia

Jeremie Zerbit et al.

LEUKEMIA & LYMPHOMA (2021)

添加到收藏夹

Article Oncology

Blinatumomab plus ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

Marie-Anne Couturier et al.

Summary: The study retrospectively examined the efficacy of a new chemo-free approach combining blinatumomab with ponatinib in treating Ph+ ALL patients, showing promising results with most patients achieving complete remission. Differences were observed in relapse/progression rates between allo and non allo cases, highlighting the need for further research to confirm the findings. Prospective studies are warranted to evaluate the safety, tolerability, and efficacy of the combination therapy.

LEUKEMIA & LYMPHOMA (2021)

添加到收藏夹

Article Medicine, General & Internal